Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension

References

• World Health Organization. Mortality and Burden of Disease Attributable to Selected Major Risks. 2009; http://www.who.int/healthinfo/global_burden_disease/
   Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27–32.
   PubMed Web of Science ®Google Scholar
• Panza JA, Quyyumi AA, , Brush JE JrEpstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27.
   PubMed Web of Science ®Google Scholar
• Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, . Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46:518–523.
   PubMed Web of Science ®Google Scholar
• Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens. 1993;7:193–194.
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, van der Arend BJ, . Pulse-wave analysis: Clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol. 2002;22:147–152.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens. 2007;25: 1751–1762.
   PubMed Web of Science ®Google Scholar
• Kals J, Kampus P, Kals M, Teesalu R, Zilmer K, Pulges A, . Arterial elasticity is associated with endothelial vasodilatory function and asymmetric dimethylarginine level in healthy subjects. Scand J Clin Lab Invest. 2007;67: 536–544.
   PubMed Web of Science ®Google Scholar
• , Brosius FC 3rdHostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, . Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease. Circulation. 2006;114:1083–1087.
   PubMedGoogle Scholar
• Kals J, Kampus P, Kals M, Pulges A, Teesalu R, Zilmer M. Effects of stimulation of nitric oxide synthesis on large artery stiffness in patients with peripheral arterial disease. Atherosclerosis. 2006;185:368–374.
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockroft JR, . Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens. 1998;16:2079–2084.
   PubMed Web of Science ®Google Scholar
• Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, . Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104: 191–196.
   PubMed Web of Science ®Google Scholar
• McEniery CM, Wallace S, Mackenzie IS, McDonnell B, , YasminNewby DE, . Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. 2006;48:602–608.
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994; 24:1468–1474.
   PubMed Web of Science ®Google Scholar
• Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032–2037.
   PubMed Web of Science ®Google Scholar
• Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, . Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592–1600.
   PubMed Web of Science ®Google Scholar
• Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24:1912–1919.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, . Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet. 2001;358: 2113–2117.
   PubMed Web of Science ®Google Scholar
• Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, . Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. 2006;26:2536–2540.
   PubMed Web of Science ®Google Scholar
• Pasini AF, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S, . Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251–1257.
   PubMed Web of Science ®Google Scholar
• Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, . Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension. 2002;39:10–15.
   PubMed Web of Science ®Google Scholar
• Chirinos JA, David R, Bralley JA, Zea-Díaz H, Muñoz-Atahualpa E, Corrales-Medina F, . Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: The PREVENCION Study. Hypertension. 2008;52:1051–1059.
   PubMed Web of Science ®Google Scholar
• Wallace SM, , YasminMcEniery CM, Mäki-Petäjä KM, Booth AD, Cockcroft JR, . Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50:228–233.
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, . Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172–177.
   PubMed Web of Science ®Google Scholar
• Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, . Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455–1459.
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, . Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation. 1999;99:1141–1146.
   PubMed Web of Science ®Google Scholar
• Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol. 2005;45: 1980–1986.
   PubMed Web of Science ®Google Scholar
• Lundman P, Eriksson MJ, Stühlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001;38:111–116.
   PubMed Web of Science ®Google Scholar
• Sobczak A, Goniewicz ML, Szoltysek-Boldys I. ADMA and SDMA levels in healthy men exposed to tobacco smoke. Atherosclerosis. 2009;205:357–359.
   PubMed Web of Science ®Google Scholar
• Maas R, Schulze F, Baumert J, Löwel H, Hamraz K, Schwedhelm E, . Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: Prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem. 2007; 53:693–701.
   PubMed Web of Science ®Google Scholar
• Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism. 2004;53:1574–1579.
   PubMed Web of Science ®Google Scholar